natgillin/translations-raw huggingface dataset:
is selected from the group consisting of H, alkyl, and R4b; 
R? je odabran iz skupine koju čine H, alkil i RY;
The composition as defined in claim 9, said composition being in the form of a solution, a gel or an emulsion. 
Spoj prema zahtjevu 9, naznačen time što je farmaceutski pripravak u obliku otopine, gela ili emulzije.
Hand truck (1) according to Claim 9, in which the lifting device is driven, via a cylinder (17,54) and a pulley and cable system (51,52,53,55,56,57,59,60,61,62,63), in both an upward lifting direction and a downward pushing direction. 
Ručna kolica (1) u skladu s patentnim zahtjevom 9, naznačena time što se uređaj za podizanje održava u pogonu pomoću cilindra (17, 54) i sustava kotura i kabela (51, 52, 53, 55, 56, 57, 59, 60, 61, 62, 63), kako u smjeru podizanja prema gore tako i u smjeru spuštanja prema dolje.
Because of the complex internal structure of the heat exchanger 70, frequent cleaning is very important for the shelf life of the drink, especially if this consists of beer. 
Zbog kompleksne unutrašnje strukture izmjenjivača topline 70, vrlo važno je često čišćenje kako bi se osigurao dugotrajni rok upotrebe pića, pogotovo ako se radi o pivu.
A composite composition comprising a carbon nanostructure network according to any one of the preceding claims, and a polymer. The composite composition according to claim 8, comprising the network in an amount of 0.1 - 10 wt%, based on total polymer weight in the composite composition. 
Kompozicija kompozitnog materijala u skladu s patentnim zahtjevom 5, naznačena time što se navedena mreža dodaje u količinama od 0.1 - 10 tež%, na bazi ukupne težine polimera u kompoziciji kompozitnog materijala.
The device of any preceding claim in the form of a catheter, a stent, an implantable or insertable tube, dental braces or dentures. 
Uređaj iz bilo kojeg prethodnog zahtjeva u obliku katetera, stenta, ugradbene ili umetne cijevi, zubnih proteza ili umjetnih zubala.
DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION 
Datum podnošenja europske prijave patenta:
The fungicidal composition according to Claim 9, wherein a bivalent alcohol is used as a viscosity reductant. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da se dvovalentni alkohol koristi kao sredstvo za redukciju viskoziteta.
Pharmaceutical composition comprising a modified oligonucleotide according to any of claims 1-15. 
Farmaceutski sastav koji sadrži nukleotid prema patentnom zahtjevu 1 ili 2.
crystallizing compound of formula (IV) in a solvent comprising methyl isobutyl ketone to obtain a suspension, and ii) removing the solvent from the suspension. 
CIVI, taj postupak obuhvaća: i) kristalizaciju spoja formule (IV) u otapalu koje sadrži metil izobutil keton radi dobivanja suspenzije, i 1i) "uklanjanje otapala iz suspenzije.
The reaction may also be carried out in the presence of 1-hydroxybenzotriazole in conjunction with a suitable coupling agent, such as a carbodiimide. 
Reakcija se također može provesti u prisutnosti 1-hidroksibenzotriazola u kombinaciji sa odgovarajućim agensom za spajanje, popu karbodiimida.
and X12 are independently a natural or unnatural amino acid selected from C, c, hC, D-hC, wherein the side chain of X6 and X12 are linked together via a covalent bond forming a disulfide; and wherein the N-terminus and the C-terminus optionally form a ring together with 1, 2, 3 or 4 glycine amino acids; or an amide, an ester or a salt of the polypeptide; wherein Nle is L-norleucine; D-hC is D-homocysteine; hC is L-homocysteine; 
X6 i X12 su neovisno prirodna ili neprirodna amino kiselina odabrana od €, c, hC, D-hC, pri čemu su bočni lanci od X6 i X12 međusobno povezani preko kovalentne veze koja tvori disulfid; te time, da N-terminalni kraj i C-terminalni kraj opcijski tvore prsten zajedno s 1, 2, 3 ili 4 glicinskih amino kiselina; ili amid, ester ili sol polipeptida; dok pritom Nle je L-norleukin, D-hC je D-homocistein; hC je L-homocistein;
A bispecific antibody or antibody fragment thereof that specifically binds to IL-13 and IL-4, wherein the bispecific antibody or antibody fragment thereof is an IgG molecule that is a heterotetramer composed of two heavy and two light chains, wherein the heavy chains consist of two variables heavy chain domains (VH1 - VH2) deriving from two different antibodies joined together by a linker composed of ten amino acids (G4S)2 and fused to the IgG4 constant domain, wherein the light chains consist of two variables light domains (VL1-VL2) deriving from two different antibodies joined together by a linker composed of ten amino acids (G4S)2 and fused to the constant kappa region, and wherein the two different antibodies are an antibody specifically binding IL-13 and an antibody specifically binding IL-4. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 i IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLhB-B13-poveznica-VLhBD4-8-CL-C i dva teška lanca sa strukturom N-VHhB-813-poveznica-VHhBD4-8-CH1-CH2-CH3-C, pri čemu VLhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLh8D4-3 sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHh8D4-8 sadrži sekvencu aminokiseline SEQ ID NO: 5, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
A toothbrush according to claim 2 in which the first and second axes are substantially perpendicular. 
Četkica za zube (10) sukladno zahtjevu 2 pri čemu su prva i druga os supstancijalno okomite.
The processes of claim 1, wherein the coke drum vapor outlet temperature in said coking unit is operated at: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da temperatura izlazne pare koksnog bubnja u
The compound of claim 14 or 15 wherein R17 is OH or OR18. 
Spoj u skladu s patentnim zahtjevom 14 ili 15, naznačen time, da R17 je OH ili OR18.
Figure 10 is a plan view of the sheet metal strip on termination of the stretching stage, 
je pogled s gornje strane na limenu metalnu traku na završetku faze rastezanja, slika 11
The resulting solid is dissolved in ethyl acetate (2 ml) and triturated with iso-hexane (7 ml) to yield the titled compound as a white solid. 
Dobivenu krutu tvar se otopi u etil acetatu (2 ml) 1 triturira s izo-heksanom (7 ml), čime se dobije naslovni spoj kao bijela kruta tvar.
The pharmaceutical composition or package for use according to claim 9, wherein the amount of glatiramer acetate is 100 mg/day. 
Farmaceutski sastav ili pakiranje za uporabu u skladu s patentnim zahtjevom 9, naznačeni time, da količina glatiramer acetata jest 100 mg/dnevno.
The method of claim 40 wherein the biologically active or chemical substance comprises at least in part living organisms. 
Postupak prema zahtjevu 40, naznačen time što se biološki aktivna ili kemijska supstanca sastoji bar dijelom od živih organizama.
a light chain selected from the group consisting of SEQ ID NOs: 49, 53, and 54. 
laki lanac odabran iz skupine koju čine SEQ ID NO: 49, 53, i 54.
According to another preferred embodiment of the process according to the present invention, the ground calcium carbonate and/or the precipitated calcium carbonate is in the form of a powder or in the form of slurry. 
Postupak prema zahtjevu 1, naznačen time da je prirodni kalcijev karbonat i/ili taložni kalcijev karbonat u obliku praha ili u obliku suspenzije.
The method of any of claims 9 to 12, wherein the second pulse amplitude modulation (PAM) scheme is a modified version of the first. 
Metoda prema zahtjevima 9 do 12, naznačena time da je druga shema pulsnoamplitudne modulacije (PAM) modificirana verzija prve sheme.
Host cell comprising the vector of claim 4 or a nucleic acid molecule of claim 1 and 2, whereby the host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, and may be a prokaryotic cell, such as a bacterial cell. 
Stanica domaćin, naznačena time da sadrži vektor prema zahtjevu 6 ili molekulu nukleinske kiseline prema zahtjevu 5, pri čemu stanica domaćin je viša eukariotska stanica domaćin, niža eukariotska stanica domaćin, ili prokariotska stanica. Stanica domaćin prema zahtjevu 7, naznačena time da viša eukariotska stanica domaćin je stanica sisavca.
The method of claim 1, wherein the reperfusion therapy is performed after determining the primate qualifies for reperfusion based on lack of a completed infarction, an ischemic penumbra and lack of hemorrhage as shown by CT, MRI or PET analysis. The method of claim 20, wherein the reperfusion therapy is performed at least 12 or at least 24 hours after onset of ischemia. 
Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se reperfuzijsku terapiju provodi najmanje 12 ili najmanje 24 sata nakon početka ishemije, ili što se reperfuzijsku terapiju provodi 275-690 minuta nakon početka ishemije.
In certain embodiments, the present invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least: at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and mg hydromorphone hydrochloride; and wherein the composition comprises at least about 92% (by wt) polyethylene oxide. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži 8 mg hidromorfon hidroklorida, te najmanje oko 94 % (težinski) polietilen oksida. Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži 12 mg hidromorfon hidroklorida, te najmanje oko 92 % (težinski) polietilen oksida.
represents a heteroaralkyl or a substituted heteroaralkyl, 
predstavlja heteroaralkil ili supstituirani heteroaralkil;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
The compound according to claim 7, wherein is aryl, wherein said aryl is unsubstituted or substituted with 1 or 2 substituent(s) R6; 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da R, je aril, pri čemu je rečeni aril nesupstituiran ili supstituiran s 1 ili 2 supstituenta R4;
a homologue of a fragment of the sequence of (i), which sequence is capable of tolerising an individual to the sequence of (i) and has a length of at least 9 amino acids, and wherein said homologue has at least 70% homology to any 9 contiguous amino acids in the sequence of (i). 
homologni fragment sekvence od (i), sekvenca je sposobna na toleranciju pojedinca na sekvencu od (i) i ima duljinu od najmanje 9 aminokiselina, pri čemu navedeni homologni ima najmanje 70% homologije na bilo kojih 9 dodirnih aminokiselina u sekvenci od (i).
We also demonstrated the synergistic effect by using a converse administration schedule, i.e. 
Mi smo također pokazali sinergistički učinak upotrebom konverznog plana davanja, tj.
A protein comprising SEQ ID NO: 29 or 30. 
Protein, naznačen time što ima SEQ ID NO: 29 ili 30.
Acidic catalysts in Step B) in a process according to the present invention include common acidic catalysts which may be used for the conversion of fructose into furan derivatives. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time, da se pretvorba D- fruktoze u furanske derivate u koraku B) provodi pod mikrovalnim grijanjem.
wherein Hal, R1 and R2 have the same meaning as in formula (I). 
Ha! gdje Hal, R! i RŽ imaju isto značenje kao u formuli (I).
The method of claim 1 or claim 2, wherein the non-human animal does not express functional classical endogenous MHC I, II a, and II B polypeptides from the endogenous non-human MHC locus on a cell surface. 
Životinja prema zahtjevu 1, naznačena time, da životinja ne izražava funkcionalne endogene MHC-I-, II-a- i II-B-polipeptide iz endogenih ne-humanih MHC-loci na površinu stanice.
A compound according to any one of claims 1 to 61, for use in accordance with claim 57 as a medicament for the treatment of a disease or condition where inhibition of PDE5 is known, or can be shown, to produce a beneficial effect. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 61, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 57 kao medikament za liječenje bolesti ili stanja za koje se zna, ili se može pokazati, da inhibiranje PDE5 daje povoljan učinak,
Time (minutes) 
Stopa protoka (minute)
about 200 millibars to about 800 millibars; 
(ii) od oko 200 milibara pa do 800 milibara;
In some embodiments, the particle contrast agent can include Crystal Violet New Methylene Blue in amounts sufficient to result in a ratio of the Crystal Violet to the New Methylene Blue between about 1:1 to about 1:500 under staining conditions. The saponin can be included in amounts sufficient to result in concentrations between about 50 mg/L and about 750 mg/L under staining conditions. 
Kristal violet i Novo metilensko modrilo u dovoljnoj količini da se dobiju omjer Kristal violet prema Novom metilenskom modrilu između oko 1:1 do oko 1:500 u uvjetima bojenja; i glutaraldehid u dovoljnoj količini da se dobiju koncentracije od ili ispod 0.1% u uvjetima bojenja; i inkubiranje smjese uzorka obuhvaća grijanje smjese uzorka manje od 60 sekundi.
In particular, the invention provides compounds possessing the combined effect of serotonin reuptake inhibition and norepinephrine reuptake inhibition. 
Izum, pogotovo, daje na raspolaganje spojeve koji posjeduju kombinirani učinak inhibicije re-apsorocije serotonona i norepinefrina.
reacting 1,3-cyclohexadiene with CH≡CHC(O)OR1 in the presence of an aluminum catalyst to form Compound (Q) wherein R1 is C1-4 alkyl and 
(i) reakciji 1,3-cikloheksadiena s CH=CHC(O)OR', u prisutnosti aluminijskog katalizatora, kako bi se dobilo Spoj (Q)
a compound of the formula (VI) 
[B] spoj s formulom (VI)
The antisense oligonucleotide of claim 3, wherein the oligonucleotide is chemically linked to a polyethylene glycol chain. 
Antisens oligonukleotid u skladu sa zahtjevom 16, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na polietilen-glikolski lanac.
The composition according to Claim 2 or 3, which contains the anthranilamide compound; a nonionic surfactant and/or an anionic surfactant as the dispersant; and at least one hydrophilic organic solvent selected from the group consisting of N,N-dimethylacetamide, dimethylsulfoxide, Y-butyrolactone, N-methyl-2-pyrrolidone and cyclohexanone. 
Pripravak u skladu s patentnim zahtjevom 2 ili 3, naznačen time, da sadržava antranilamidni spoj; neionski surfaktant i / ili anionski surfaktant kao sredstvo za disperziranje; i najmanje jedno hidrofilno organsko otapalo odabrano iz skupine koju čine N,N-dimetilacetamid, dimetilsulfoksid, g-butirolakton, N-metil-2-pirolidon i cikloheksanon.
The monoclonal antibody for the use according to any one of claims 1 to 4, wherein said antibody is selected from the group consisting of antibody Bax69, as defined as having a nucleic acid sequence in VL of SEQ ID NO:14 and a nucleic acid sequence in VH of SEQ ID NO:20, antibody Bax94, as defined as having a nucleic acid sequence in VL of SEQ ID NO:16 and a nucleic acid sequence in VH of SEQ ID NO:22, antibody Bax152, as defined as having a nucleic acid sequence in VL of SEQ ID NO:17 and a nucleic acid sequence in VH of SEQ ID NO:23, and antibody BaxA10, as defined as having a nucleic acid sequence in VL of SEQ ID NO:18 and a nucleic acid sequence in VH of SEQ ID NO:24. 
Monoklonalno protutijelo prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da je spomenuto protutijelo odabrano iz skupine koja se sastoji od sljedećih: protutijelo Bax69, dok je protutijelo Bax69 definirano tako da ima sekvencu nukleinske kiseline u Vr od SEQ ID NO:14 i sekvencu nukleinske kiseline u Vg od SEQ ID NO:20, protutijelo Bax94, dok je protutijelo Bax94 definirano tako da ima sekvencu nukleinske kiseline u VL od SEQ ID NO:16 1 sekvencu nukleinske kiseline u Vg od SEQ ID NO:22, protutijelo Bax152, dok je protutijelo Bax152 definirano tako da ima sekvencu nukleinske kiseline u Vr od SEQ ID NO:17 i sekvencu nukleinske kiseline u Vg od SEQ ID NO:23, i protutijelo BaxA10, dok je protutijelo BaxA10 definirano tako da ima sekvencu nukleinske kiseline u VL od SEQ ID NO:18 i sekvencu nukleinske kiseline u Vg od SEQ ID NO:24.
measuring, in the pharmaceutical formulation obtained in step b), the concentration of free macrocyclic chelate Cch l and/or free lanthanide Clan l; 
mjerenje u farmaceutskoj formulaciji dobivenoj u koraku b) koncentracije slobodnog lantanida Clan 1; a koncentracija slobodnog makrocikličkog kelata Cch1 jednaka je 0;
The method of claim 13 or 14 wherein step (2) comprises evaluating the acidic variants by a method selected from the group consisting of ion exchange chromatography wherein the composition is treated with sialidase, reduced capillary electrophoresis with sodium dodecyl sulfate (CE-SDS), non-reduced CE-SDS, boronate chromatography, and peptide mapping. 
Postupak prema zahtjevu 13 ili 14, naznačen time, da korak (2) obuhvaća procjenjivanje kiselinskih varijanti putem postupka koji je odabran iz skupine koju čine kromatografija ionske izmjene gdje se sastav obrađuje sa sialidazom, reducirana kapilarna elektroforezija s natrijevim dodecilsulfatom (CE-SDS), nereducirana CE-SDS, boronatna kromatografija i peptidno mapiranje.
The pharmaceutical composition of claim 1, wherein the compound of formula (I) is selected from: 5,6′-di(pyridin-3-yl)-5′-methyl-3-((E)-styryl)-2,3′-bipyridine; 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 7, gdje spoj sa formulom (I) je odabrano od:
This compound advanced to Phase III clinical trials for the treatment of organ transplantation and in Phase II for multiple sclerosis. 
Ovaj spoj promaknut je u 3. fazu kliničkih ispitivanja liječenja presađivanja organa, te u 2. fazu kod multiple skleroze.
The antibody or antigen-binding fragment thereof according to claim 1 further comprising a moiety selected from the group consisting of a readily detectable moiety, a directly cytotoxic moiety, and an indirectly cytotoxic moiety. 
Spoj koji sadrži antitijelo ili njegov fragment koji se vezuje za antigen prema bilo kojem patentnom zahtjevu od 1 do 4 i dodatnu skupinu, primjerice lako detektibilnu skupinu i/ili izravno ili neizravno citotoksičnu skupinu.
The method of claim 7, wherein the at least one attenuated Salmonella or the at least one inactivated Salmonella of the Salmonella D group is Salmonella Enteritidis. 
Cjepivo prema zahtjevu 4, naznačeno time, da najmanje jedna atenuirana Salmonella ili najmanje jedna neaktivirana Salmonella od Salmonella skupine D je Salmonella Enteritidis.
Use according to any of the preceding claims, wherein the component d) is selected from sulphated amino acids and derivatives thereof, 1-methionine, 1-cysteine, 1-cystine, taurine, 4-thiazolidinecarboxylic acid and/or methylsulphonylmethane. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time, da je sastojak d) odabran između aminokiselina koje sadrže sumpornu grupu i njihovih derivata, 1-metionina, 1-cisteina, 1-cistina, taurina, 4-tiazilidinkarboksilne kiseline i/ili metilsulfonilmetana.
The dosage of the active ingredient is of the order of magnitude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units. 
Doza aktivnog sastojka je reda raspona uobičajenog za inhibitore PDE, te je moguće dnevnu dozu primijeniti kao jediničnu ili u više dozirnih jedinica.
water is added to the melphalan flufenamide solution in order to obtain an aqueous melphalan flufenamide solution, in a concentration of about 0.2-3.0 mg/ml; 
dodaje se voda otopini melfalan flufenamid hidroklorida (Jl) da bi se dobila vodena otopina melfalan flufenamid hidroklorida (J1), u koncentraciji od 0,2 - 3,0 mg/ml;
(ANOVA, Duncan's multiple range test, p=0.000189). 
(ANOVA, Duncanov test za višestruko područje, p = 0,000189).
The method according to claim 11, wherein the cleaning element comprises a cloth or brush. 
Postupak sukladno zahtjevu 7 ili 8, pri čemu je element za čišćenje krpica ili četkica.
<400> 6 Use of HuLuc63 in the preparation of a first medicament, said HuLuc63 being a humanized IgG1 antibody having a heavy chain variable region corresponding to SEQ ID NO:5 and a light chain variable region corresponding to SEQ ID NO:6, and the use of lenalidomide in the preparation of a second medicament, said medicaments for use in the treatment of multiple myeloma, wherein the first medicament is administered concurrently, prior to or following the administration of the second medicament. 
UporabaHuL.uc63 za pripremu jednog prvog lijeka, pri čemu je taj HuL.uc63 humanizirano IgG1 antitijelo koje ima jednu varijabilnu regiju teškog lanca koja odgovara sekvenci SEQ ID NO:5 i jednu varijabilnu regiju lakog lanca koja odgovara sekvenci SEQ ID NO:6, te uporaba lenalidomida za pripremu jednog drugog lijeka, s time da se spomenuti lijekovi koriste za liječenje multiplog mijeloma, pri čemu se prvi lijek daje istovremeno, prije ili nakon davanja drugog lijeka.
The actual amounts of reconstituting fluid are not limiting features of embodiments of this invention. 
Stvarne količine rekonstruirane tekućine nisu ograničavajuće karakteristike varijanti ovog izuma.
A process for preparing an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone, comprising the steps: 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 15 ppm.
Rotigotine drug substance comprising at least 5% of a polymorphic form of Rotigotine as defined in any one of claims 1-2. 
Rotigotin ljekovita supstanca koja sadrži najmanje 5% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
A convenient displaceable group Lg is, for example, a halogeno, alkanesulfonyloxy or arylsulfonyloxy group, for example a chloro, bromo, methanesulfonyloxy, 4-nitrobenzenesulfonyloxy or toluene-4-sulfonyloxy group (suitably a methanesulfonyloxy, 4-nitrobenzenesulfonyloxy or toluene-4-sulfonyloxy group). 
Prikladna izlazna skupina Lg je, na primjer, halogeno, alkansulfoniloksi ili arilsulfoniloksi skupina, na primjer kloro, bromo, metansulfoniloksi, 4-nitrobenzensulfoniloksi ili toluen-4-sulfoniloksi skupina (poželjno metansulfoniloksi, 4-nitrobenzensulfoniloksi ili toluen-4-sulfoniloksi skupina).
The process of claim 1, further comprising mixing a triacylglycerides-containing oil (2) with water (10) and diatomic hydrogen (14) to form the triacylglycerides-water-diatomic hydrogen mixture (16). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća miješanje ulja (2) koje sadržava triacilgliceride s vodom (10) i molekularnim vodikom (14) radi dobivanja smjese triacilglicerida, vode i molekularnog vodika (16).
receiving second data from a second plurality of reactions involving cell-free nucleic acid molecules from the biological sample, wherein the second data includes: 
Postupak prema zahtjevu 1, naznačen time, da su molekule nukleinske kiseline iz biološkog uzorka obogaćene za sekvence manje od 300 bp.
Therefore its availability is likely to be diminished by the application of an enteric coat to the tablet which will delay core dissolution until the tablet reaches the intestine. 
Prema tome, vjerojatno je da njegova bioraspoloživost bude smanjena nanošenjem enteričke ovojnice na tabletu, koja će odgoditi otapanje jezgre dok tableta ne dosegne crijevo.